Skip to main content

Table 4 Median and range for MSQoL by treatment, with p-value and standardized effect size, d

From: Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)

Measure Treatment
A: Placebo B: Melatonin p d
Median Range Median Range
Mental Overall Score 68.0 16–92 75.0 28–92 0.110 0.446
Physical Overall Score 44.0 17–89 48.5 21–90 0.023 0.651
Energy Score 30.0 0–76 36.0 0–84 0.212 0.347
Emotional Wellbeing 68.0 32–100 72.0 32–100 0.961 0.013
Physical Health 45.0 5–100 40.0 5–100 0.701 0.105
Role limitations due to physical problems 12.5 0–100 25.0 0–100 0.015 0.701
Role limitations due to emotional problems 100 0–100 100 0–100 0.580 0.151
Health Perceptions 42.5 5–85 45.0 0–80 0.396 0.233
Social Function 67.0 25–100 67.0 0–100 0.603 0.142
Cognitive Function 67.0 0–100 73.0 0–100 0.884 0.040
Health Distress 60.0 15–90 60.0 0–100 0.862 0.036
Change in Health 25.0 0–50 50.0 25–100 0.647 0.125
Quality of Life 55.0 27–95 63.0 0–90 0.130 0.421
Pain Score 78.0 0–100 70.0 0–100 0.029 0.622